Skip to main content

Advertisement

SpringerLink
Log in

Clinical characteristics, disease trajectories and management of vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic (VEXAS) syndrome: a systematic review

  • Systematic Review
  • Published:
Rheumatology International Aims and scope Submit manuscript

Abstract

Background

VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome is a newly discovered autoinflammatory condition characterised by somatic mutation of the UBA1 gene. The syndrome leads to multi-system inflammation affecting predominantly the skin, lungs and bone marrow.

Methods

We undertook a systematic review of the multisystem features and genotypes observed in VEXAS syndrome. Articles discussing VEXAS syndrome were included. Medline, Embase and Cochrane databases were searched.

Information was extracted on: demographics, type and prevalence of clinical manifestations, genetic mutations and treatment. Meta-analysis using a random effects model was used to determine pooled estimates of serum markers.

Results

From 303 articles, 90 were included, comprising 394 patients with VEXAS. 99.2% were male, with a mean age of 67.1 years (SD 8.5) at disease onset.

The most frequent diagnoses made prior to VEXAS were: relapsing polychondritis (n = 59); Sweet’s syndrome (n = 24); polyarteritis nodosa (n = 11); and myelodysplastic syndrome (n = 10). Fever was reported in 270 cases (68.5%) and weight loss in 79 (20.1%). Most patients had haematological (n = 342; 86.8%), dermatological (n = 321; 81.5%), pulmonary (n = 297; 75.4%%) and musculoskeletal (n = 172; 43.7%) involvement, although other organ manifestations of varying prevalence were also recorded.

The most commonly reported mutations were “c.122T > C pMET41Thr” (n = 124), “c.121A > G pMET41Val” (n = 62) and “c.121A > C pMet41Leu” (n = 52).

Most patients received glucocorticoids (n = 240; 60.9%) followed by methotrexate (n = 82; 20.8%) and IL-6 inhibitors (n = 61, 15.4%). One patient underwent splenectomy; 24 received bone marrow transplants.

Conclusion

VEXAS syndrome is a rare disorder affecting predominantly middle-aged men. This is the first systematic review to capture clinical manifestations, genetics and treatment of reported cases. Further studies are needed to optimise treatment and subsequently reduce morbidity and mortality.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

Data availability

Data available upon reasonable request.

References

  1. Grayson PC, Patel BA, Young NS (2021) VEXAS syndrome. Blood [Internet]. 2021 Jul 1 [cited 2023 Jul 8];137(26):3591–4. https://pubmed.ncbi.nlm.nih.gov/33971000/. Accessed 8 July 2023

  2. Beck DB, Ferrada MA, Sikora KA, Ombrello AK, Collins JC, Pei W et al (2020) Somatic mutations in UBA1 and severe adult-onset autoinflammatory disease. N Engl J Med [Internet]. 383(27):2628–2638. https://doi.org/10.1056/NEJMoa2026834

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Levy-Lahad E, King MC (2020) Hiding in plain sight—somatic mutation in human disease. N Engl J Med [Internet]. 383(27):2680–2682. https://doi.org/10.1056/NEJMe2030754

    Article  CAS  PubMed  Google Scholar 

  4. Ruffer N, Krusche M (2023) VEXAS syndrome: a diagnostic puzzle. RMD Open [Internet]. 2023 Aug 1 [cited 2023 Aug 13];9(3):e003332. https://rmdopen.bmj.com/content/9/3/e003332

  5. Beck DB, Bodian DL, Shah V, Mirshahi UL, Kim J, Ding Y, et al (2023) Estimated prevalence and clinical manifestations of UBA1 variants associated with VEXAS syndrome in a clinical population. JAMA [Internet]. 2023 Jan 24 [cited 2023 Aug 13];329(4):318–24. https://jamanetwork.com/journals/jama/fullarticle/2800661

  6. Beck DB, Bodian DL, Shah V, Mirshahi UL, Kim J, Ding Y, et al (2023) Estimated prevalence and clinical manifestations of UBA1 variants associated with VEXAS syndrome in a clinical population. JAMA [Internet]. 2023 Jan 24 [cited 2023 Aug 23];329(4):318–24. https://jamanetwork.com/journals/jama/fullarticle/2800661

  7. Ferrada MA, Sikora KA, Luo Y, Wells K V., Patel B, Groarke EM, et al (2021) Somatic mutations in UBA1 define a distinct subset of relapsing polychondritis patients with VEXAS. Arthritis Rheumatol [Internet]. 2021 Oct 1 [cited 2023 Aug 23];73(10):1886–95. https://pubmed.ncbi.nlm.nih.gov/33779074/

  8. Beck DB, Ferrada MA, Sikora KA, Ombrello AK, Collins JC, Pei W, et al (2020) Somatic MUtations in UBA1 and severe adult-onset autoinflammatory disease. N Engl J Med [Internet]. 2020 Dec 31 [cited 2023 Aug 23];383(27):2628–38. https://pubmed.ncbi.nlm.nih.gov/33108101/

  9. Ruffer N, Krusche M (2023) VEXAS syndrome: a diagnostic puzzle. RMD Open [Internet]. 2023 Aug 1 [cited 2023 Aug 23];9(3):e003332. https://rmdopen.bmj.com/content/9/3/e003332

  10. Oganesyan A, Jachiet V, Chasset F, Hirsch P, Hage-Sleiman M, Fabiani B, et al (2021) VEXAS syndrome: still expanding the clinical phenotype. Rheumatology (Oxford) [Internet]. 2021 Sep 1 [cited 2023 Aug 13];60(9):E321–3. https://pubmed.ncbi.nlm.nih.gov/33693570/

  11. Nguyen JK, Routledge D, van Der Weyden C, Blombery P, Angel CM, Johnson D, et al (2022) VEXAS syndrome: a dermatological perspective. Australas J Dermatol [Internet]. 2022 Nov 1 [cited 2023 Aug 23];63(4):488–92. https://pubmed.ncbi.nlm.nih.gov/36197697/

  12. Hines AS, Mohandesi NA, Lehman JS, Koster MJ, Cantwell HM, Alavi A et al (2023) Cutaneous involvement in VEXAS syndrome: clinical and histopathologic findings. Int J Dermatol [Internet] 62(7):938–945. https://doi.org/10.1111/ijd.16635

    Article  CAS  PubMed  Google Scholar 

  13. Kouranloo K, Ashley A, Zhao SS, Dey M (2023) Pulmonary manifestations in VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome: a systematic review. Rheumatol Int [Internet]. 2023 Jun 1 [cited 2023 Aug 23];43(6):1023–32. https://pubmed.ncbi.nlm.nih.gov/36617363/

  14. Casal Moura M, Baqir M, Tandon YK, Samec MJ, Hines AS, Reichard KK, et al (2023) Pulmonary manifestations in VEXAS syndrome. Respir Med [Internet]. 2023 Jul 1 [cited 2023 Aug 23];213. https://pubmed.ncbi.nlm.nih.gov/37062498/

  15. Grayson PC, Patel BA, Young NS (2021) VEXAS syndrome. Blood [Internet]. 137(26):3591

    CAS  PubMed  PubMed Central  Google Scholar 

  16. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ [Internet]. 2021 Mar 29 [cited 2023 Oct 6];372. https://www.bmj.com/content/372/bmj.n71

  17. PROSPERO [Internet]. [cited 2023 Aug 6]. https://www.crd.york.ac.uk/prospero/#myprospero

  18. Yildirim F, Erdogan M, Yalcin Mutlu M, Akkuzu G, Ozgur DS, Karaalioglu B, et al (2023) VEXAS syndrome with severe multisystem involvement: Rapid recovery after splenectomy. Int J Rheum Dis [Internet]. 26(3):559–62. https://authproxy.bma.org.uk/process/redirects?url=https://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=36544349

  19. Al-Hakim A, Poulter JA, Mahmoud D, Rose AMS, Elcombe S, Lachmann H et al (2022) Allogeneic haematopoietic stem cell transplantation for VEXAS syndrome: UK experience. Br J Haematol [Internet] 199(5):777–781. https://doi.org/10.1111/bjh.18488

    Article  PubMed  Google Scholar 

  20. Koster MJ, Kourelis T, Reichard KK, Kermani TA, Beck DB, Cardona DO, et al (2021) Clinical heterogeneity of the VEXAS syndrome: a case series. Mayo Clin Proc [Internet]. 96(10):2653–9. https://authproxy.bma.org.uk/process/redirects?url=https://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med20&AN=34489099

  21. Stiburkova B, Pavelcova K, Belickova M, Magaziner SJ, Collins JC, Werner A, et al (2023) Novel somatic UBA1 variant in a patient with VEXAS syndrome. Arthritis Rheumatol [Internet]. 10:10. https://authproxy.bma.org.uk/process/redirects?url=https://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medp&AN=36762418

  22. Stubbins RJ, McGinnis E, Johal B, Chen LY, Wilson L, Cardona DO, et al (2022) VEXAS syndrome in a female patient with constitutional 45,X (Turner syndrome). Haematologica [Internet]. 2022;107(4):1011–3. https://authproxy.bma.org.uk/process/redirects?url=https://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med21&AN=34911285

  23. Pozdniakova H, Vedire A, Kadakia A, Imburgio S, Bajwa R, Gupta V et al (2023) A double hit to ubiquitination leading to a new diagnosis of VEXAS syndrome. J Med Cases Internet. 14(9–10):327

    Article  Google Scholar 

  24. Mascaro JM, Rodriguez-Pinto I, Poza G, Mensa-Vilaro A, Fernandez-Martin J, Caminal-Montero L, et al (2023) Spanish cohort of VEXAS syndrome: clinical manifestations, outcome of treatments and novel evidences about UBA1 mosaicism. Ann Rheum Dis [Internet]. 2023 [cited 2023 Oct 30]; https://pubmed.ncbi.nlm.nih.gov/37666646/

  25. Casal Moura M, Baqir M, Tandon YK, Samec MJ, Hines AS, Reichard KK, et al (2023) Pulmonary manifestations in VEXAS syndrome. Respir Med [Internet]. 2023 Jul 1 [cited 2023 Aug 13];213. https://pubmed.ncbi.nlm.nih.gov/37062498/

  26. Bourbon E, Heiblig M, Gerfaud Valentin M, Barba T, Durel CA, Lega JC et al (2021) Therapeutic options in VEXAS syndrome: insights from a retrospective series. Blood [Internet] 137(26):3682–3684. https://doi.org/10.1182/blood.2020010177

    Article  CAS  PubMed  Google Scholar 

  27. Ferrada MA, Sikora KA, Luo Y, Wells K V, Patel B, Groarke EM, et al (2021) Somatic mutations in UBA1 define a distinct subset of relapsing polychondritis patients with VEXAS. Arthritis Rheumatol [Internet]. 73(10):1886–95. Available from: https://authproxy.bma.org.uk/process/redirects?url=https://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med19&AN=33779074

  28. Khitri MY, Guedon AF, Georgin-Lavialle S, Terrier B, Saadoun D, Seguier J, et al (2022) Comparison between idiopathic and VEXAS-relapsing polychondritis: analysis of a French case series of 95 patients. RMD Open [Internet] 2022 Jul 1 [cited 2023 Aug 13];8(2):e002255. https://rmdopen.bmj.com/content/8/2/e002255

  29. Matsumoto H, Asano T, Tsuchida N, Maeda A, Yoshida S, Yokose K, et al (2022) Behcet’s disease with a somatic UBA1 variant: expanding spectrum of autoinflammatory phenotypes of VEXAS syndrome. Clin Immunol [Internet]. 2022;238:108996. https://authproxy.bma.org.uk/process/redirects?url=https://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med21&AN=35398520

  30. Midtvedt O, Stray-Pedersen A, Andersson H, Gunnarsson R, Tveten K, Ali MM, et al (2022) A man in his sixties with chondritis and bone marrow failure. Tidsskrift for Den Norske Laegeforening [Internet]. 142(4):01. https://authproxy.bma.org.uk/process/redirects?url=https://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med21&AN=35239266

  31. Muratore F, Marvisi C, Castrignano P, Nicoli D, Farnetti E, Bonanno O, et al (2022) VEXAS syndrome: a case series from a single-center cohort of Italian patients with vasculitis. Arthritis Rheumatol [Internet] 74(4):665–70. https://authproxy.bma.org.uk/process/redirects?url=https://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med21&AN=34611997

  32. Obiorah IE, Patel BA, Groarke EM, Wang W, Trick M, Ombrello AK, et al (2021) Benign and malignant hematologic manifestations in patients with VEXAS syndrome due to somatic mutations in UBA1. Blood Adv [Internet]. 5(16):3203–15. https://authproxy.bma.org.uk/process/redirects?url=https://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med20&AN=34427584

  33. Rasch MNB, Szabados F, Jensen JMB, Nielsen KO, Hauge EM, Troldborg A (2022) Patients with VEXAS diagnosed in a Danish tertiary rheumatology setting have highly elevated inflammatory markers, macrocytic anaemia and negative autoimmune biomarkers. RMD Open [Internet] 8. https://authproxy.bma.org.uk/process/redirects?url=https://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=emed23&AN=2020239150

  34. van der Made CI, Potjewijd J, Hoogstins A, Willems HPJ, Kwakernaak AJ, de Sevaux RGL, et al (2022) Adult-onset autoinflammation caused by somatic mutations in UBA1: A Dutch case series of patients with VEXAS. J Allergy Clin Immunol [Internet]. 149(1):432–439.e4. https://authproxy.bma.org.uk/process/redirects?url=https://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med21&AN=34048852

  35. Casal Moura M, Baqir M, Tandon YK, Samec MJ, Hines AS, Reichard KK, et al (2023) Pulmonary manifestations in VEXAS syndrome. Respir Med [Internet]. 2023 Jul 1 [cited 2023 Oct 30];213. https://pubmed.ncbi.nlm.nih.gov/37062498/

  36. Pinto FR, Lamas A, Oliveira DG, Oliveira ME, Faria R (2023) VEXAS syndrome: a call for diagnostic awareness based on a case series of seven patients. Acta Med Port [Internet]. 2023 May 1 [cited 2023 Oct 30];36(5):379–80. https://pubmed.ncbi.nlm.nih.gov/37071935/

  37. Hines AS, Koster MJ, Bock AR, Go RS, Warrington KJ, Olteanu H et al (2023) Targeted testing of bone marrow specimens with cytoplasmic vacuolization to identify previously undiagnosed cases of VEXAS syndrome. Rheumatology. https://doi.org/10.1093/rheumatology/kead245

    Article  PubMed  Google Scholar 

  38. Salehi T, Callisto A, Beecher MB, Hissaria P (2023) Tofacitinib as a biologic response modifier in VEXAS syndrome: a case series. Int J Rheum Dis [Internet]. 2023 [cited 2023 Oct 30]; https://pubmed.ncbi.nlm.nih.gov/37337622/

  39. Kouranloo K, Ashley A, Zhao SS, Dey M (2023) Pulmonary manifestations in VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome: a systematic review. Rheumatol Int [Internet] 43(6):1023–1032. https://doi.org/10.1007/s00296-022-05266-2

    Article  PubMed  Google Scholar 

  40. Stiburkova B, Pavelcova K, Belickova M, Magaziner SJ, Collins JC, Werner A, et al (2023) Novel somatic UBA1 variant in a patient with VEXAS syndrome. Arthritis Rheumatol [Internet]. 2023 Jul 1 [cited 2023 Oct 30];75(7):1285–90. https://pubmed.ncbi.nlm.nih.gov/36762418/

  41. Oo TM, Koay JTJ, Lee SF, Lee SMS, Lim XR, Fan BE (2022) Thrombosis in VEXAS syndrome. J Thromb Thrombolysis [Internet]. 53(4):965–70. https://authproxy.bma.org.uk/process/redirects?url=https://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med21&AN=34817788

  42. Nguyen JK, Routledge D, van Der Weyden C, Blombery P, Angel CM, Johnson D, et al (2022) VEXAS syndrome: a dermatological perspective. Australas J Dermatol [Internet]. 63(4):488–92. https://authproxy.bma.org.uk/process/redirects?url=https://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med22&AN=36197697

  43. Zakine E, Schell B, Battistella M, Vignon-Pennamen MD, Chasset F, Mahevas T, et al (2021) UBA1 Variations in neutrophilic dermatosis skin lesions of patients with VEXAS syndrome. JAMA Dermatol [Internet] 57(11):1349–54. https://authproxy.bma.org.uk/process/redirects?url=https://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med20&AN=34495287

  44. Georgin-Lavialle S, Terrier B, Guedon AF, Heiblig M, Comont T, Lazaro E et al (2022) Further characterization of clinical and laboratory features in VEXAS syndrome: large-scale analysis of a multicentre case series of 116 French patients. Br J Dermatol [Internet] 186(3):564–574. https://doi.org/10.1111/bjd.20805

    Article  CAS  PubMed  Google Scholar 

  45. Ferrada MA, Savic S, Cardona DO, Collins JC, Alessi H, Gutierrez-Rodrigues F et al (2022) Translation of cytoplasmic UBA1 contributes to VEXAS syndrome pathogenesis. Blood 140(13):1496–1506

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Beck DB, Bodian DL, Shah V, Mirshahi UL, Kim J, Ding Y, et al (47) Genomic ascertainment for UBA1 variants and VEXAS syndrome: a population-based study. medRxiv [Internet]. 2022 Aug 1 [cited 2023 Oct 1];2022.07.27.22277962. https://doi.org/10.1101/2022.07.27.22277962v1

  47. Dehghan N, Marcon KM, Sedlic T, Beck DB, Dutz JP, Chen LYC (2021) Vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic (VEXAS) syndrome: fevers, myalgia, arthralgia, auricular chondritis, and erythema nodosum. The Lancet [Internet]. 2021 Aug 14 [cited 2023 Aug 13];398(10300):621. http://www.thelancet.com/article/S0140673621014306/fulltext

  48. Collantes-Rodríguez C, Jiménez-Gallo D, de la Varga- MR, Mora-López F, Garrastazul-Sánchez MP, Linares-Barrios M (2023) Vexas syndrome successfully treated with canakinumab. JDDG Journal der Deutschen Dermatologischen Gesellschaft Internet. 21(1):69–70. https://doi.org/10.1111/ddg.14933

    Article  Google Scholar 

  49. Euvrard R, Fournier T, Georgescu D, Bourbon E, Sujobert P, Lega JC, et al (2021) VEXAS syndrome-related AA amyloidosis: a case report. Rheumatology (Oxford) [Internet]. 2021 Jan 1 [cited 2023 Aug 13];61(1):E15–6 https://pubmed.ncbi.nlm.nih.gov/34498034/

  50. Guerrero-Bermudez CA, Cardona-Cardona AF, Ariza-Parra EJ, Arostegui JI, Mensa-Vilaro A, Yague J, et al (2022) Vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic syndrome (VEXAS syndrome) with prominent supraglottic larynx involvement: a case-based review. Clin Rheumatol [Internet] 41(11):3565–72. https://authproxy.bma.org.uk/process/redirects?url=https://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med22&AN=35986821

  51. Horton RK, Zheng G (2021) A case of VEXAS syndrome with subtle morphologic findings. Blood [Internet] 138(15):1378. https://authproxy.bma.org.uk/process/redirects?url=https://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med20&AN=34647982

  52. Kunishita Y, Kirino Y, Tsuchida N, Maeda A, Sato Y, Takase-Minegishi K, et al (2022) Case report: tocilizumab treatment for VEXAS syndrome with relapsing polychondritis: a single-center, 1-Year longitudinal observational study In Japan. Front Immunol [Internet] 13:901063. https://authproxy.bma.org.uk/process/redirects?url=https://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med22&AN=35769485

  53. Lytle A, Bagg A (2021) VEXAS: a vivid new syndrome associated with vacuoles in various hematopoietic cells. Blood [Internet] 137(26):3690. https://authproxy.bma.org.uk/process/redirects?url=https://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med20&AN=34196684

  54. Neupane K, Jayarangaiah A, Zhang Y, Kumar A (2022) VEXAS syndrome with progression of MDS to MDS/MPN overlap syndrome. BMJ Case Rep [Internet]. 15(12):22. https://authproxy.bma.org.uk/process/redirects?url=https://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=36549759

  55. Tsuchida N, Kunishita Y, Uchiyama Y, Kirino Y, Enaka M, Yamaguchi Y, et al (2021) Pathogenic UBA1 variants associated with VEXAS syndrome in Japanese patients with relapsing polychondritis. Ann Rheum Dis [Internet] 80(8):1057–61. https://authproxy.bma.org.uk/process/redirects?url=https://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med19&AN=33789873

  56. Sánchez-Hernández BE, Calderón-Espinoza I, Martín-Nares E (2023) Challenging the paradigm: a case of early-onset VEXAS syndrome. Rheumatology [Internet]. https://doi.org/10.1093/rheumatology/kead506

    Article  PubMed  PubMed Central  Google Scholar 

  57. Podvin B, Cleenewerck N, Nibourel O, Marceau-Renaut A, Roynard P, Preudhomme C et al (2023) Three UBA1 clones for a unique VEXAS syndrome. Rheumatology. https://doi.org/10.1093/rheumatology/kead472

    Article  PubMed  Google Scholar 

  58. Al-Hakim A, Cull A, Topping J, Nadat F, Milek J, Alhefzi R, et al (2023) Recovery of bone marrow function in VEXAS syndrome-potential role for romiplostim. Hemasphere [Internet]. 2023 Aug 26 [cited 2023 Oct 30];7(8):E934. https://pubmed.ncbi.nlm.nih.gov/37520777/

  59. Kunimoto H, Miura A, Maeda A, Tsuchida N, Uchiyama Y, Kunishita Y, et al (2023) Clinical and genetic features of Japanese cases of MDS associated with VEXAS syndrome. Int J Hematol [Internet]. 2023 Oct 1 [cited 2023 Oct 30];118(4). https://pubmed.ncbi.nlm.nih.gov/37062784/

  60. Ross C, Elfassy HL, Makhzoum JP (2021) Somatic mutation in UBA1 and ANCA-associated Vasculitis. J Rheumatol [Internet] 1. https://authproxy.bma.org.uk/process/redirects?url=https://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=emexb&AN=635233348

  61. Thomas B, Campagne J (2022) Vexas: A new syndrome not always associated with hemopathy. EJHaem [Internet]. 3(1):235. https://authproxy.bma.org.uk/process/redirects?url=https://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=pmnm7&AN=35846195

  62. Oka H, Sumitomo S, Nishikubo M, Yamashita D, Maruoka H, Shiroishi Y et al (2023) VEXAS syndrome with granulomatosis with polyangiitis manifestation: retained in remission using methotrexate and infliximab. Rheumatology. https://doi.org/10.1093/rheumatology/kead536

    Article  PubMed  Google Scholar 

  63. Fan BE, Cao L, Gallardo CA, Lee SMS, Koh LW, Goh LL, et al (2021) Myeloid and lymphoid vacuolation in VEXAS syndrome. Am J Hematol [Internet]. 96(8):1056–7. https://authproxy.bma.org.uk/process/redirects?url=https://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med19&AN=33460492

  64. Matsuki Y, Kawai R, Suyama T, Katagiri K, Kanazawa N, Inaba Y (2022) A case of VEXAS syndrome with myositis possibly associated with macrophage activation syndrome. J Dermatol [Internet]. 49(12):e441–3. https://authproxy.bma.org.uk/process/redirects?url=https://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med22&AN=35924490

  65. Staels F, Betrains A, Woei AJF, Boeckx N, Beckers M, Bervoets A, et al (2021) Case Report: VEXAS syndrome: from mild symptoms to life-threatening macrophage activation syndrome. Front Immunol [Internet]. 2021;12:678927. https://authproxy.bma.org.uk/process/redirects?url=https://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med20&AN=34046042

  66. Boyadzhieva Z, Ruffer N, Kötter I, Krusche M (2023) How to treat VEXAS syndrome: a systematic review on effectiveness and safety of current treatment strategies. Rheumatology. https://doi.org/10.1093/rheumatology/kead240

    Article  PubMed  Google Scholar 

  67. Gurnari C, McLornan DP (2022) Update on VEXAS and role of allogeneic bone marrow transplant: considerations on behalf of the Chronic Malignancies Working Party of the EBMT. Bone Marrow Transplant 2022 57:11 [Internet]. 2022 Aug 8 [cited 2023 Aug 6];57(11):1642–8. https://www.nature.com/articles/s41409-022-01774-8

  68. Hage-Sleiman M, Lalevee S, Guermouche H, Favale F, Chaquin M, Battistella M, et al (2021) Dominance of an UBA1 mutant clone over a CALR mutant clone: from essential thrombocytemia to VEXAS. Haematologica [Internet]. 2021;106(12):3245–8. https://authproxy.bma.org.uk/process/redirects?url=https://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med20&AN=34320791

  69. Heiblig M, Ferrada MA, Koster MT, Barba T, Gerfaud-Valentin M, Mékinian A et al (2022) Ruxolitinib is more effective than other JAK inhibitors to treat VEXAS syndrome: a retrospective multicenter study. Blood 140(8):927–931

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  70. Argobi Y (2022) VEXAS syndrome with cutaneous nodules. Dermatol Reports [Internet]. 2022;14(2):9414. https://authproxy.bma.org.uk/process/redirects?url=https://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=pmnm7&AN=35795842

  71. Austestad J, Madland TM, Sandnes M, Haslerud TM, Benneche A, Reikvam H (2023) VEXAS syndrome in a patient with myeloproliferative neoplasia. Case Rep Hematol [Internet]. 2023 Feb 25 [cited 2023 Aug 13];2023:1–7. https://pubmed.ncbi.nlm.nih.gov/36879894/

  72. Balu B, Ding Y, Junkins-Hopkins JM (2023) VEXAS syndrome: diagnostic clues for dermatologists. Int J Dermatol [Internet]. 2023 [cited 2023 Aug 13]; https://pubmed.ncbi.nlm.nih.gov/36841896/

  73. Barba T, Jamilloux Y, Durel CA, Bourbon E, Mestrallet F, Sujobert P et al (2021) VEXAS syndrome in a woman. Rheumatology [Internet] 60(11):e402–e403. https://doi.org/10.1093/rheumatology/keab392

    Article  PubMed  Google Scholar 

  74. Battipaglia G, Vincenzi A, Falconi G, Fiore A, D’Agostino F, Iannotta R, et al (2023) New scenarios in Vacuoles, E1 enzyme, X linked, Autoinflammatory, Somatic (VEXAS) syndrome: Evolution from myelodysplastic syndrome to acute myeloid leukemia. Curr Res Transl Med [Internet]. 2023 Apr 1 [cited 2023 Oct 30];71(2). https://pubmed.ncbi.nlm.nih.gov/36905702/

  75. Beecher M, Tong J, Halliday L, Hissaria P, Selva D (2022) Recurrent dacryoadenitis associated with VEXAS syndrome. Clin Exp Ophthalmol [Internet]. 50:934. https://authproxy.bma.org.uk/process/redirects?url=https://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=emexa&AN=639618442

  76. Belicard F, Belhomme N, Bouzy S, Saillard C, Nedelec F, Mear JB, et al (2023) Vacuoles, E1 enzyme, X-linked, autoinflammatory, and somatic syndrome in the intensive care unit: a case report. J Med Case Rep [Internet]. 2023 Dec 1 [cited 2023 Oct 30];17(1). https://pubmed.ncbi.nlm.nih.gov/37480098/

  77. Campochiaro C, Tomelleri A, Cavalli G, De Luca G, Grassini G, Cangi MG, et al (2022) Successful use of cyclosporin A and interleukin-1 blocker combination therapy in VEXAS syndrome: a single-center case series. Arthritis Rheumatol [Internet]. 2022 Jul 1 [cited 2023 Aug 13];74(7):1302–3. https://pubmed.ncbi.nlm.nih.gov/35212178/

  78. Ciferská H, Gregová M, Klein M, Šenolt L, Maaloufová JS, Pavelka K, et al (2022) VEXAS syndrome: a report of three cases. Clin Exp Rheumatol [Internet]. 2022 Jul 1 [cited 2023 Aug 13];40(7):1449. https://pubmed.ncbi.nlm.nih.gov/35238760/

  79. Fabian L, Luca S, Adela S, Britta M (2021) Genetic double strike: VEXAS and TET2 positive myelodysplastic syndrome in a patient with long-standing refractory autoinflammatory disease. Case Report. Swiss Med Wkly [Internet]. 2021;151:5S. https://authproxy.bma.org.uk/process/redirects?url=https://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=emed22&AN=636023872

  80. Fagart A, Quemeneur T, Collet G, Demailly F, Rousselin C (2023) A “Leopard Man” Aspect on 18 F-FDG PET/CT Revealing a VEXAS Syndrome. Clin Nucl Med [Internet]. 48(1):e33–4. https://authproxy.bma.org.uk/process/redirects?url=https://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med22&AN=36252945

  81. Fahmy LM, Schreidah CM, Lapolla BA, Magro CM, Geskin LJ (2023) VEXAS syndrome presenting as refractory cutaneous Kikuchi disease-like inflammatory pattern responding to tofacitinib. JAAD Case Rep [Internet]. 2023 Aug 1 [cited 2023 Oct 30];38:136–40. https://pubmed.ncbi.nlm.nih.gov/37521198/

  82. Fanlo P, Román ML de S, Fonollosa A, Ilarramendi J, Heras H, Grayson P (2023) Episcleritis and periorbital edema secondary to VEXAS syndrome. Arch Soc Esp Oftalmol [Internet]. 2023 Oct [cited 2023 Oct 30];98(10). https://pubmed.ncbi.nlm.nih.gov/37595794/

  83. Fenu EM, Bagg A (2023) VEXAS’d by lymphadenopathy: an unusual case of extramedullary hematopoiesis. Blood [Internet]. 2023 Jun 1 [cited 2023 Oct 30];141(22):2784. https://pubmed.ncbi.nlm.nih.gov/37261849/

  84. Goyal A, Narayanan D, Wong W, Laga AC, Connell NT, Ritter SY, et al (2022) Tocilizumab for treatment of cutaneous and systemic manifestations of vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic (VEXAS) syndrome without myelodysplastic syndrome. JAAD Case Rep [Internet]. 23:15–9. https://authproxy.bma.org.uk/process/redirects?url=https://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=pmnm7&AN=35391910

  85. Grambow-Velilla J, Braun T, Pop G, Louzoun A, Soussan M (2023) Aortitis PET Imaging in VEXAS syndrome: a case report. Clin Nucl Med [Internet]. 48(2):e67–8. https://authproxy.bma.org.uk/process/redirects?url=https://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=36607374

  86. Grosse A, Salehi T, Callary M, Hecker JR, Hissaria P (2022) VEXAS syndrome causing fever of unknown origin. Med J Australia [Internet]. 217(3):129–30. https://authproxy.bma.org.uk/process/redirects?url=https://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med22&AN=35793067

  87. Haines P, Pullarkat S, Said J (2023) VEXAS syndrome: Vacuoles in myeloid, erythroid, and lymphoid lineages. Int J Lab Hematol [Internet]. 2023 [cited 2023 Oct 30]; https://pubmed.ncbi.nlm.nih.gov/37674280/

  88. Himmelmann A, Brucker R (2021) The VEXAS Syndrome: uncontrolled inflammation and macrocytic anaemia in a 77-year-old male patient. Eur J Case Rep Intern Med [Internet]. 8(4):002484. https://authproxy.bma.org.uk/process/redirects?url=https://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=pmnm6&AN=33987129

  89. Huang H, Zhang W, Cai W, Liu J, Wang H, Qin T, et al (2021) VEXAS syndrome in myelodysplastic syndrome with autoimmune disorder. Exp Hematol Oncol [Internet]. 10(1):23. https://authproxy.bma.org.uk/process/redirects?url=https://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=pmnm6&AN=33741056

  90. Islam S, Cullen T, Sumpton D, Damodaran A, Heath D, Bosco A, et al (2022) VEXAS syndrome: lessons learnt from an early Australian case series. Intern Med J [Internet]. 52(4):658–62. https://authproxy.bma.org.uk/process/redirects?url=https://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med22&AN=35419965

  91. Itagane M, Teruya H, Kato T, Tsuchida N, Maeda A, Kirino Y, et al (2022) Clinical images: VEXAS syndrome presenting as treatment-refractory polyarteritis nodosa. Arthritis Rheumatol [Internet]. 74(11):1863–4. https://authproxy.bma.org.uk/process/redirects?url=https://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med22&AN=35696330

  92. Kao RL, Jacobsen AA, Billington Jr. CJ, Yohe SL, Beckman AK, Vercellotti GM, et al (2022) A case of VEXAS syndrome associated with EBV-associated hemophagocytic lymphohistiocytosis. Blood Cells Mol Dis [Internet]. 93:102636. https://authproxy.bma.org.uk/process/redirects?url=https://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med21&AN=34864445

  93. Kataoka A, Mizumoto C, K, a J, Iwasaki M, Sakurada M, et al (2023) Successful azacitidine therapy for myelodysplastic syndrome associated with VEXAS syndrome. Int J Hematol [Internet]. 14:14. https://authproxy.bma.org.uk/process/redirects?url=https://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medp&AN=36641501

  94. Li P, Venkatachalam S, Ospina Cordona D, Wilson L, Kovacsovics T, Moser KA, et al (2022) A clinical, histopathological, and molecular study of two cases of VEXAS syndrome without a definitive myeloid neoplasm. Blood Adv [Internet]. 6(2):405–9. Available from: https://authproxy.bma.org.uk/process/redirects?url=https://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med21&AN=34649277

  95. Lohaus N, Schaab J, Schaer D, Balabanov S, Huellner MW (2023) VEXAS syndrome with tracheal involvement but absence of vasculitis in FDG PET/CT. Clin Nucl Med [Internet]. 2023 Sep 1 [cited 2023 Oct 30];48(9):E444–5. https://pubmed.ncbi.nlm.nih.gov/37418279/

  96. Lokhande A, Jarmale S, Vaishnav YJ, Schaefer J (2023) An Orbital Manifestation of VEXAS Syndrome. Ophthalmic Plast Reconstr Surg [Internet]. 2023 Jul 4 [cited 2023 Oct 30]; https://pubmed.ncbi.nlm.nih.gov/37405738/

  97. Matsubara A, Tsuchida N, Sakurai M, Maeda A, Uchiyama Y, Sasaki K, et al (2022) A case of VEXAS syndrome with Sweet’s disease and pulmonary involvement. Journal of Dermatology [Internet]. 49(5):e177–8. Available from: https://authproxy.bma.org.uk/process/redirects?url=https://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med21&AN=35166394

  98. Matsumoto H, Fujita Y, Fukatsu M, Ikezoe T, Yokose K, Asano T, et al (2022) Case Report: Coexistence of Multiple Myeloma and Auricular Chondritis in VEXAS Syndrome. Front Immunol [Internet]. 13:897722. https://authproxy.bma.org.uk/process/redirects?url=https://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med22&AN=35757758

  99. Miyoshi Y, Kise T, Morita K, Okada H, Imadome KI, Tsuchida N, et al. Long-term remission of VEXAS syndrome achieved by a single course of CHOP therapy: a case report. Mod Rheumatol Case Rep [Internet]. 2023 Jul 24 [cited 2023 Oct 30]. https://pubmed.ncbi.nlm.nih.gov/37548220/

  100. Mohammed TO, Alavi A, Aghazadeh N, Koster MJ, Olteanu H, Mangaonkar AA, et al (2022) Vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic (VEXAS) syndrome: a presentation of two cases with dermatologic findings. Int J Dermatol [Internet]. 1:01. https://authproxy.bma.org.uk/process/redirects?url=https://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medp&AN=35230710

  101. Myint K, Patrao N, Vonica O, Vahdani K (2023) Recurrent superior orbital fissure syndrome associated with VEXAS syndrome. J Ophthalmic Inflamm Infect [Internet] 13(1):1–5. https://doi.org/10.1186/s12348-023-00362-1

    Article  Google Scholar 

  102. Rieu JB, El Kassir A, Largeaud L, Dion J, Comont T, Mansat-De Mas V (2021) Characteristic vacuolisation of granulocytic and erythroid precursors associated with VEXAS syndrome. Br J Haematol [Internet]. 194(1):8. Available from: https://authproxy.bma.org.uk/process/redirects?url=https://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med19&AN=33651376

  103. Robert M, Berleur M, Gaudemer A, Crow YJ, Frémond ML, Sacré K (2023) VEXAS syndrome: expanding the clinical and molecular spectrum. Jt Bone Spine [Internet]. 2023 May 1 [cited 2023 Oct 30];90(3). https://pubmed.ncbi.nlm.nih.gov/36690065/

  104. Sallés M, Fustà X, Lidia C, Esquius M, Mínguez S (2023) Systemic lupus erythematosus in the elderly finally diagnosed with VEXAS syndrome. Clin Exp Rheumatol [Internet] 2023 May 26 [cited 2023 Oct 30]. https://pubmed.ncbi.nlm.nih.gov/37470230/

  105. Shaukat F, Hart M, Burns T, Bansal P (2022) UBA1 and DNMT3A mutations in VEXAS syndrome. A case report and literature review. Mod Rheumatol Case Rep [Internet] 6(1):134–9. https://authproxy.bma.org.uk/process/redirects?url=https://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med21&AN=34480172

  106. Takahashi N, Takeichi T, Nishida T, Sato J, Takahashi Y, Yamamura M, et al (2021) Extensive multiple organ involvement in VEXAS syndrome. Arthritis Rheumatol [Internet] 73(10):1896–7. https://authproxy.bma.org.uk/process/redirects?url=https://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med20&AN=33881233

  107. Tosato F, Pelloso M, Zuin J, Basso D (2023) Peripheral blood cells vacuoles in VEXAS syndrome. Am J Hematol [Internet] 98(10):1663–4. https://pubmed.ncbi.nlm.nih.gov/37073682/

  108. Tozaki N, Tawada C, Niwa H, Mizutani Y, Shu E, Kawase A, et al (2022) A case of VEXAS syndrome (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) with decreased oxidative stress levels after oral prednisone and tocilizumab treatment. Front Med (Lausanne) [Internet] 9:1046820. https://authproxy.bma.org.uk/process/redirects?url=https://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=pmnm&AN=36544501

  109. Valor-Méndez L, Sticherling M, Zeschick M, Atreya R, Schmidt FD, Waldfahrer F et al (2023) VEXAS syndrome mimicking lupus-like disease. Rheumatology [Internet] 62(9):e271–e272. https://doi.org/10.1093/rheumatology/kead076

    Article  PubMed  Google Scholar 

  110. Varadarajan A, Verghese R, Tirlangi PK, Dass J, Soneja M, Seth T (2022) VEXAS syndrome (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic). Qjm [Internet]. 21:21. https://authproxy.bma.org.uk/process/redirects?url=https://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medp&AN=36409014

  111. Vu KT, Wolfe RM, Lambird JE, Maracaja DLV (2023) A case of VEXAS syndrome presenting with unusual bone marrow granulomas: a diagnostic dilemma. BMC Rheumatol [Internet] 7(1):1–6. https://doi.org/10.1186/s41927-023-00343-w

    Article  Google Scholar 

  112. Yamaguchi H, Kobayashi D, Nakamura G, Aida R, Horii Y, Okamoto T, et al (2023) Acute heart failure due to left common iliac arteriovenous fistula: a case of VEXAS syndrome. Mod Rheumatol Case Rep [Internet] 7(1):327–33. https://authproxy.bma.org.uk/process/redirects?url=https://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=36264203

Download references

Funding

No funding to declare.

Author information

Authors and Affiliations

  1. Department of Rheumatology, East Surrey Hospital, Canada Avenue, Redhill, RH1 5RH, UK

    Koushan Kouranloo

  2. School of Medicine, Cedar House, University of Liverpool, Ashton Street, Liverpool, L69 3GE, UK

    Koushan Kouranloo

  3. Centre for Rheumatic Diseases, Weston Education Centre, Cutcombe Road, London, SE5 9RJ, UK

    Mrinalini Dey

  4. Liverpool University NHS Foundation Trust, Prescot Street, Liverpool, L7 8XP, UK

    Jude Almutawa

  5. British Medical Association Library, BMA House, Tavistock Square, London, WC1H 9JP, UK

    Nikki Myall

  6. Department of Rheumatology, Southport & Ormskirk Hospital NHS Trust, Town Lane, Kew, Southport, PR8 6PN, UK

    Arvind Nune

Authors
  1. Koushan Kouranloo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mrinalini Dey
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jude Almutawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Nikki Myall
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Arvind Nune
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

All co-authors take full responsibility for the integrity and accuracy of all aspects of the work.

Corresponding author

Correspondence to Koushan Kouranloo.

Ethics declarations

Conflict of interest

Authors KK, MD, JA, NM and AN declare no conflicts of interest.

Ethical approval

Not applicable.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Below is the link to the electronic supplementary material.

Supplementary file1 (DOCX 12 KB)

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kouranloo, K., Dey, M., Almutawa, J. et al. Clinical characteristics, disease trajectories and management of vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic (VEXAS) syndrome: a systematic review. Rheumatol Int (2023). https://doi.org/10.1007/s00296-023-05513-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s00296-023-05513-0

Keywords

Search

Navigation